- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02768987
Bright 1 Bodies Weight Management Program (B1B)
Bright 1 Bodies: Extending the Bright Bodies Weight Management Program to Adolescents With Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prevalence of overweight among patients with type 1 diabetes (T1D) of all ages has grown at alarming rates since the 1980s. Physical inactivity occurs among 65% to 95% of youth with T1D and doubles their risk of overweight. A major factor limiting their physical activity appears to be self-managed problem solving around exercise such as adjustments to insulin and diet, which is practiced regularly by less than half of our adolescent patients with T1D and less frequently than any other self-management behavior. Our previous interventions applying coping skills training (ABCs of Diabetes and TeenCope) as well as diabetes self-management (Managing Diabetes) successfully improved problem-solving and other aspects of self-management along with health outcomes among adolescents with T1D, but did not focus on those who were overweight nor promotion of physical activity and weight loss. The Yale Bright Bodies intensive lifestyle program successfully promotes physical activity and weight loss, enrolling >100 overweight youth from greater New Haven annually but does not presently accommodate those with T1D.
The purpose of the present study is to pilot test a 12-week intensive lifestyle program for adolescents with overweight and T1D utilizing group exercise classes from Bright Bodies adapted for this population, supplemented with coping skills training and diabetes self-management education to address problem solving behaviors that limit their physical activity and weight control. Our primary aim is to evaluate the changes in physical activity adherence, anthropometrics (body mass index percentile for age, body fat percentage), and self-management behaviors following this 12-week lifestyles program among sedentary adolescents with T1D and overweight (n=25, OW) compared with sedentary adolescents with T1D and normal weight (n=25, NW). We hypothesize that the OW group will achieve improve physical activity adherence and anthropometrics to the same or greater extent as the NW group and previous Bright Bodies cohorts, and that these changes will correlate with improved exercise-related problem solving.
Although physical activity is recommended for weight loss, outcomes from increased physical activity have been heterogeneously distributed-not all overweight participants lose weight and some even gain weight. Furthermore the etiologies of overweight/obesity and T1D appear to interact, yet no study has tested the influence of physical activity upon biological pathways related to overweight/obesity for patients with T1D. Accordingly, our secondary aim is to evaluate changes in adipocytokines and epigenetic factors related to the etiology of overweight/obesity following our physical activity intervention. We hypothesize changes in these biomarkers will correlate with changes in anthropometry variables and partially explain any differences in response between the groups and individuals should those occur.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale Children's Diabetes Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient of the Yale-New Haven Hospital (YNHH) Pediatrics Long Wharf or Trumbull Diabetes Clinic
- Diagnosed with T1D
- 11 to 19 years old
- Sedentary (exercise less than twice per week over past two months)
- n=25 overweight (BMI > 85th percentile for age and sex according to Centers for Disease Control Growth Charts) and n=25 normal weight
- Family willing to commit the time and effort to a family-based lifestyle program.
Exclusion Criteria:
- Endocrinopathies other than type 1 diabetes; adequately treated hypothyroidism, as demonstrated by normal thyroid tests within previous six months, is allowed.
- Concurrent use of systemic (oral, parenteral) glucocorticoids or other medications known to contribute to obesity; inhaled steroids are allowed.
- Any use of pharmacological intervention for weight management, including prescription medication, over the counter medication, or herbal supplements.
- Chronic disease or physical disability that would influence treatment intervention or preclude participation in regular physical activity (e.g., chronic renal failure).
- Psychological conditions such as uncontrolled eating disorder, psychosis, personality disorders and other disorders that will interfere with the ability to maintain complete follow up and adherence to protocol.
- Any concurrent membership in a comprehensive weight management program.
- Inability or unwillingness of the parent to accompany the child to nutrition classes.
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Overweight
Sedentary adolescents with T1D and overweight
|
A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
|
EXPERIMENTAL: Normal Weight
Sedentary adolescents with T1D and normal weight
|
A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline body mass index (BMI) over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline in daily physical activity energy expenditure over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Progressive Aerobic Cardiovascular Endurance Run score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline in blood pressure over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline daily insulin usage over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline lipid profile over 12 weeks
Time Frame: Baseline, 12 weeks
|
Baseline, 12 weeks
|
Change from baseline adipocytokines over 12 weeks
Time Frame: Baseline, 12 weeks
|
Baseline, 12 weeks
|
Change from baseline inflammatory factors including C-reactive protein, interleukin-6, fibrinogen, and plasminogen activator inhibitor-1 over 12 weeks
Time Frame: Baseline, 12 weeks
|
Baseline, 12 weeks
|
Change from baseline micro RNA expression over 12 weeks
Time Frame: Baseline, 12 weeks
|
Baseline, 12 weeks
|
Change from baseline pediatric quality of life questionnaire score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline diabetes self-care inventory score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline hypoglycemia fear survey score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline psychosocial determinants of physical activity behavior questionnaire score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline self-perception profile for adolescents questionnaire social acceptance subscale score over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline in handgrip strength over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline in sit-and-reach test over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Change from baseline in push-up test over 24 weeks
Time Frame: Baseline, 12 weeks, 24 weeks
|
Baseline, 12 weeks, 24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Garrett I Ash, PhD, CSCS, Yale University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1605017843
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Bright 1 Bodies
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingObesity, ChildhoodUnited States
-
Yale UniversityNational Institutes of Health (NIH); National Center for Research Resources...CompletedImpaired Glucose ToleranceUnited States
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
Ain Shams UniversityAssiut UniversityCompleted
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompleted
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
University of ArizonaUniversity of North Texas Health Science CenterRecruitingEffectiveness of BIM in Reducing Disordered Eating Among Student Athletes | Effectiveness of BIM in Reducing Body Image Concerns Among Student Athletes | Effectiveness of BIM Improving Psychological Well-Being Among Student AthletesUnited States
-
Ain Shams UniversityActive, not recruiting
-
Vanderbilt University Medical CenterCompleted
-
NoblewellCompletedSystolic Heart Failure | Peripheral Chemoreceptor HypersensitivityPoland